As Biotech M&A Activity Gingerly Rises, Regeneron Makes Moves On Checkmate
Paying $250m For Vidutolimod Developer
Executive Summary
Regeneron hopes to bolster its immuno-oncology pipeline with the acquisition of Checkmate, which joins a spate of similar deals suggesting renewed interest in biotech investment despite an industry-wide slowdown.
You may also be interested in...
Regeneron Buys Partner Decibel Outright
Deal Snapshot: Regeneron will buy Decibel for about $109m, plus a contingent value right linked to milestones related to gene therapy programs for hearing loss.
Regeneron Takes Full Libtayo Rights As March Into Oncology Progresses
The company will pay $900m upfront to buy Sanofi's stake in the PD-1 inhibitor, which is a cornerstone of Regeneron's strategy to build an oncology portfolio.
Deal Watch: Dragonfly Adds Gilead To Its List Of Big-Name Partners
AbbVie inks collaboration and option deal focused on targeted protein degradation with Plexium. Cend and Calabrius merge in an all-stock transaction.